Loading stock data…
DRIO
$7.30+0.16 (+2.17%)
Market ClosedLast close May 1
DarioHealth Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DarioHealth Corp. in the Healthcare sector is trading at $7.30. The stock is currently near its 52-week low of $5.93, remaining 33.4% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why DRIO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.30
Potential Upside
5%
Whystock Fair Value$7.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$18.50+153.4%
Range$10.00 – $28.00
Fundamentals
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$52.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.41%
Volume
Today's trading volume
2,228
Recent News
How The DarioHealth (DRIO) Story Is Shifting With New Targets Research And GLP 1 Focus
DarioHealth’s refreshed analyst narrative centers on a price target move from US$18.00 to US$18.80, a small shift that still matters if you are tracking where the Street thinks this story can go. That new US$18.80 mark is tied directly to recent commentary, including the “DarioHealth price target lowered by US$6 at Stifel, here's why” report, which folds mixed views into a single updated level. As you read on, you will see how this evolving narrative, both bullish and cautious, might shape...
DarioHealth Corp (DRIO) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
DarioHealth Corp (DRIO) reports sequential revenue growth and strong gross margins, despite a decline in annual revenue due to a legacy client non-renewal.
DarioHealth Corp. Q4 2025 Earnings Call Summary
Moby summary of DarioHealth Corp.'s Q4 2025 earnings call
DarioHealth (DRIO) Q4 2025 Earnings Transcript
Erez Raphael, Chief Executive Officer of DarioHealth Corp. He will be joined by our President and Chief Commercial Officer, Steven C. Nelson, and Chen Franco-Yehuda, our Chief Financial Officer. A copy of the release can be found on the Investor Relations page of DarioHealth Corp.’s website.
DarioHealth Q4 Earnings Call Highlights
DarioHealth (NASDAQ:DRIO) executives highlighted record commercial momentum and continued cost reductions on the company’s fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating grow